Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA. Young G, et al. Among authors: lentz sr. Thromb Res. 2016 May;141:69-76. doi: 10.1016/j.thromres.2016.02.030. Epub 2016 Mar 2. Thromb Res. 2016. PMID: 26970716 Clinical Trial.
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. de Paula EV, et al. Among authors: lentz sr. J Thromb Haemost. 2012 Jan;10(1):81-9. doi: 10.1111/j.1538-7836.2011.04549.x. J Thromb Haemost. 2012. PMID: 22470921 Free article. Clinical Trial.
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.
Lentz SR, Rangarajan S, Karim FA, Andersen PD, Arkhammar P, Rosu G, Mahlangu J. Lentz SR, et al. Blood Coagul Fibrinolysis. 2017 Apr;28(3):224-229. doi: 10.1097/MBC.0000000000000584. Blood Coagul Fibrinolysis. 2017. PMID: 27427786 Free PMC article. Clinical Trial.
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J; Pathfinder™2 Investigators. Giangrande P, et al. Among authors: lentz sr. Thromb Haemost. 2017 Jan 26;117(2):252-261. doi: 10.1160/TH16-06-0444. Epub 2016 Dec 1. Thromb Haemost. 2017. PMID: 27904904 Clinical Trial.
Haemophilia clinical care and research needs: Assessing priorities.
Chowdary P, Angchaisuksiri P, Dimsits J, Iorio A, Kavakli K, Lentz SR, Mahlangu J, McCarthy A, Kessler C. Chowdary P, et al. Among authors: lentz sr. Haemophilia. 2018 Jul;24(4):e270-e273. doi: 10.1111/hae.13544. Epub 2018 Jul 13. Haemophilia. 2018. PMID: 30004622 No abstract available.
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G. Oldenburg J, et al. Among authors: lentz sr. Haemophilia. 2018 Nov;24(6):911-920. doi: 10.1111/hae.13608. Epub 2018 Sep 24. Haemophilia. 2018. PMID: 30248217 Clinical Trial.
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A. Lentz SR, et al. Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6. Haemophilia. 2018. PMID: 30402994 Clinical Trial.
Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N, Albayrak C, Escobar M, Andre Holme P, Kearney S, Klamroth R, Misgav M, Négrier C, Wheeler A, Santagostino E, Shima M, Landorph A, Tønder SM, Lentz SR. Curry N, et al. Among authors: lentz sr. Haemophilia. 2019 May;25(3):373-381. doi: 10.1111/hae.13712. Epub 2019 Feb 28. Haemophilia. 2019. PMID: 30817066 Free PMC article. Clinical Trial.
Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E. Chowdary P, et al. Among authors: lentz sr. Res Pract Thromb Haemost. 2019 Jun 11;3(3):542-554. doi: 10.1002/rth2.12220. eCollection 2019 Jul. Res Pract Thromb Haemost. 2019. PMID: 31294338 Free PMC article.
203 results